HC Wainwright Reaffirms “Buy” Rating for CG Oncology (NASDAQ:CGON)

HC Wainwright restated their buy rating on shares of CG Oncology (NASDAQ:CGON) in a research note released on Monday morning, Benzinga reports. HC Wainwright currently has a $75.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on CGON. The Goldman Sachs Group began coverage on CG Oncology in a research report on Tuesday, February 20th. They issued a neutral rating and a $42.00 target price for the company. Cantor Fitzgerald restated an overweight rating and issued a $75.00 price objective on shares of CG Oncology in a report on Thursday, May 2nd. Finally, Morgan Stanley assumed coverage on CG Oncology in a report on Tuesday, February 20th. They set an overweight rating and a $55.00 target price on the stock.

CG Oncology Price Performance

CG Oncology stock opened at $32.43 on Monday. CG Oncology has a one year low of $28.55 and a one year high of $50.23. The business’s 50-day moving average price is $38.93.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology in the 1st quarter worth $492,000. Capstone Investment Advisors LLC acquired a new position in shares of CG Oncology in the 1st quarter valued at $806,000. Finally, TimesSquare Capital Management LLC purchased a new position in CG Oncology in the 1st quarter worth about $9,837,000. Institutional investors and hedge funds own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.